Dendreon Biotech Files for Bankruptcy, Seeks Sale

Nov 11, 2014

AP News

Dendreon, the biotechnology firm whose prostate cancer drug Provenge was once predicted to become a blockbuster, is seeking Chapter 11 bankruptcy protection with a plan that leads to either a sale of the company or a takeover by lenders.

According to AP News, the Seattle company listed more than $664 million in total debts and $364.6 million in assets in a U.S. Bankruptcy Court filing.

Despite a series of staff and cost-cutting measures over the past few years by Dendreon, sales of Provenge -- hampered by the drug’s high cost, the complexity of customizing the therapy and outside competition -- fell short of expectations and the company could not pay its huge accumulated debt. Provenge generated only $283.7 million in revenue last year.

Read the AP News release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments